Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04605484
Other study ID # P-105-201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 22, 2021
Est. completion date October 20, 2022

Study information

Verified date April 2024
Source AlloVir
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date October 20, 2022
Est. primary completion date October 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who had a kidney transplant performed greater than or equal to 28 days prior to enrollment - At least 1 identified, suitably matched Posoleucel (ALVR105) cell line for infusion is available. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. - Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: - Undergone allogeneic hematopoietic cell transplantation - Evidence or history of graft versus host disease (GVHD) or cytokine release syndrome (CRS). - Uncontrolled or progressive bacterial or fungal infections - Known or presumed pneumonia - Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose >0.5 mg/kg/day or equivalent). - Pregnant or lactating or planning to become pregnant. - Weight <40 kg. - Patients who received, or planned to receive abatacept or belatacept, within 3 months of screening

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Posoleucel (formerly known as ALVR105) cells
Infusion
Placebo (visually identical to Posoleucel)
Infusion

Locations

Country Name City State
United States University of Michigan Medical Center Ann Arbor Michigan
United States Piedmont Hospital Atlanta Georgia
United States John Hopkins Hospital Baltimore Maryland
United States University of Maryland Medical Center Baltimore Maryland
United States Harvard Medical School - Brigham & Women's Hospital Boston Massachusetts
United States Erie County Medical Center Buffalo New York
United States Medical University of South Carolina Charleston South Carolina
United States University of Virginia Charlottesville Virginia
United States Northwestern University Transplant Center Chicago Illinois
United States University of Cincinnati Hospital Cincinnati Ohio
United States Cleveland Clinic Foundation Cleveland Ohio
United States Baylor University Medical Center Dallas Texas
United States UT Southwestern Medical Center Dallas Texas
United States Duke University Durham North Carolina
United States Inova Fairfax Medical Center Falls Church Virginia
United States UPMC Pinnacle-Harrisburg Hospital Harrisburg Pennsylvania
United States Indiana University Hospital Indianapolis Indiana
United States University of Kansas Hospital Kansas City Kansas
United States Keck Medical Center of USC Los Angeles California
United States North Shore University Hospital Manhasset New York
United States Loyola University Medical Center Maywood Illinois
United States University of Minnesota Minneapolis Minnesota
United States Tulane University School of Medicine New Orleans Louisiana
United States NYU Langone Medical Center New York New York
United States Weil Medical College - NY Presbyterian Hospital New York New York
United States University of Nebraska Medical Center Omaha Nebraska
United States Stanford University Palo Alto California
United States UPMC Montefiore Hospital Pittsburgh Pennsylvania
United States Rhode Island Hospital Providence Rhode Island
United States Virginia Commonwealth University Richmond Virginia
United States University of California Davis Medical Center Sacramento California
United States Washington University School of Medicine Saint Louis Missouri
United States University of California, San Francisco Medical Center San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
AlloVir

Country where clinical trial is conducted

United States, 

References & Publications (2)

Chandraker A, Regmi A, Gohh R, Sharma A, Woodle ES, Ansari MJ, Nair V, Chen LX, Alhamad T, Norman S, Cibrik D, Singh M, Alper A, Jain D, Zaky Z, Knechtle S, Sharfuddin A, Gupta G, Lonze BE, Young JH, Adey D, Faravardeh A, Dadhania DM, Rossi AP, Florescu D, Cardarelli F, Ma J, Gilmore S, Vasileiou S, Jindra PT, Wojciechowski D. Posoleucel in Kidney Transplant Recipients with BK Viremia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. J Am Soc Nephrol. 2024 May 1;35(5):618-629. doi: 10.1681/ASN.0000000000000329. Epub 2024 Mar 12. No abstract available. — View Citation

Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs are defined as AEs with a start date and time on or after the first dose of study treatment through the end of study.
Clinically significant changes in vital signs, physical exams, laboratory assessments and electrocardiograms were also reported as TEAEs.
Day 1 to Week 24
Secondary Change From Baseline in BK Viral Load BK viral load was quantitated using polymerase chain reaction assays at the central laboratory. A negative change from baseline represents a reduction in BK viral load. Baseline and Week 24
See also
  Status Clinical Trial Phase
Withdrawn NCT02758288 - BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
Completed NCT01624948 - Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients Phase 4
Active, not recruiting NCT05026021 - Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
Recruiting NCT05511779 - Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation Phase 2
Recruiting NCT05183490 - R-MVST Cells for Treatment of Viral Infections Phase 1
Active, not recruiting NCT00684372 - BK Viremia After Renal Transplantation N/A
Recruiting NCT06219616 - Prediction of BK Virus Reactivation in Kidney Transplant Recipient N/A
Not yet recruiting NCT05264259 - New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Terminated NCT05305040 - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Terminated NCT04390113 - Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) Phase 3
Withdrawn NCT02313844 - Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B) Phase 1
Completed NCT03532971 - Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Recruiting NCT02479698 - Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus Phase 2
Recruiting NCT05101213 - Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients Phase 1
Completed NCT01789203 - Ciprofloxacin for Prevention of BK Infection Phase 4
Completed NCT04693637 - Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Recruiting NCT05618275 - Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
Recruiting NCT04542733 - The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient N/A
Recruiting NCT05042076 - BK With VST for Kidney Transplant Patients Phase 1
Completed NCT04294472 - A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients Phase 2